Antisense oligonucleotide modulation of STAT3 expression
US7098192B2 · kind B2 · utility
9Cited by
6References
21Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Feb 6, 2004 |
| Grant date | Aug 29, 2006 |
| Priority date | — |
| Expiry date | Mar 1, 2024 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02P20/582
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.